| Serial Number | 98211536 |
| Word Mark | TEPYLUTE |
| Filing Date | Thursday, October 5, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, January 21, 2025 |
| Registration Number | 7658017 |
| Registration Date | Tuesday, January 21, 2025 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, December 3, 2024 |
| Description of Mark | The mark consists of the stylized wording "TepyLute" appearing to the right of a curved design and small circular design. |
| Goods and Services | Pharmaceutical and medicinal preparations and substances for the treatment of metabolic diseases and disorders, oncological diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, viral diseases and disorders, bacterial diseases and disorders, infectious diseases and disorders, viral diseases and disorder, as well as diseases and disorders of the alimentary tract, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system, and respiratory system; pharmaceutical and medicinal preparations and substances for use in oncology; pharmaceutical preparations, products and substances for human use for the treatment of metabolic diseases and disorders, oncological diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, viral diseases and disorders, bacterial diseases and disorders, infectious diseases and disorders, viral diseases and disorder, as well as diseases and disorders of the alimentary tract, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system, and respiratory system; pharmaceutical preparations and substances for the prevention and treatment of cancer; pharmaceutical compounds for treating cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of tumours; anti-cancer drugs and pharmaceutical preparations |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Research and development services in the field of metabolic diseases and disorders, oncological diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, viral diseases and disorders, bacterial diseases and disorders, infectious diseases and disorders, viral diseases and disorder, as well as diseases and disorders of the alimentary tract, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system, and respiratory system; biological research; scientific research services; research and development services in the pharmaceutical and biotechnology fields; research services relating to the development and testing of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical product evaluation; testing and inspection of pharmaceutical preparations and medicines; product safety and quality testing in the pharmaceutical and biotechnology fields; provision of information and data relating to research and development in the pharmaceutical and biotechnology fields |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, October 14, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, October 14, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Shorla Pharma Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Clonmel, Co. Tipperary E91V329 IE |
| Party Name | Shorla Pharma Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Clonmel, Co. Tipperary E91V329 IE |
| Party Name | Shorla Pharma Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Clonmel, Co. Tipperary E91V329 IE |
| Event Date | Event Description |
| Saturday, October 14, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 17, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Thursday, April 25, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, April 25, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, April 25, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, May 10, 2024 | ASSIGNED TO EXAMINER |
| Sunday, May 12, 2024 | NON-FINAL ACTION E-MAILED |
| Sunday, May 12, 2024 | NON-FINAL ACTION WRITTEN |
| Sunday, May 12, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, August 8, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, November 4, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 4, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, November 4, 2024 | ASSIGNED TO LIE |
| Tuesday, November 5, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 27, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 3, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 3, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 21, 2025 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, January 21, 2025 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |